Brenda J Weigel1, Elizabeth Lyden1, James R Anderson1, William H Meyer1, David M Parham1, David A Rodeberg1, Jeff M Michalski1, Douglas S Hawkins1, Carola A S Arndt2. 1. Brenda J. Weigel, University of Minnesota, Minneapolis; Carola A.S. Arndt, Mayo Clinic, Rochester, MN; Elizabeth Lyden, Nebraska Medical Center, Omaha, NE; James R. Anderson, Frontier Science and Technology Research Foundation, Madison, WI; William H. Meyer, University of Oklahoma Health Sciences Center, Oklahoma City, OK; David M. Parham, Children's Hospital of Los Angeles, Los Angeles, CA; David A. Rodeberg, East Carolina University, Greenville, NC; Jeff M. Michalski, Washington University School of Medicine, St Louis, MO; and Douglas S. Hawkins, University of Washington, Seattle, WA. 2. Brenda J. Weigel, University of Minnesota, Minneapolis; Carola A.S. Arndt, Mayo Clinic, Rochester, MN; Elizabeth Lyden, Nebraska Medical Center, Omaha, NE; James R. Anderson, Frontier Science and Technology Research Foundation, Madison, WI; William H. Meyer, University of Oklahoma Health Sciences Center, Oklahoma City, OK; David M. Parham, Children's Hospital of Los Angeles, Los Angeles, CA; David A. Rodeberg, East Carolina University, Greenville, NC; Jeff M. Michalski, Washington University School of Medicine, St Louis, MO; and Douglas S. Hawkins, University of Washington, Seattle, WA. carndt@mayo.edu.
Abstract
PURPOSE: Patients with metastatic rhabdomyosarcoma (RMS), except those younger than 10 years with embryonal RMS, have an estimated long-term event-free survival (EFS) of less than 20%. The main goal of this study was to improve outcome of patients with metastatic RMS by dose intensification with interval compression, use of the most active agents determined in phase II window studies, and use of irinotecan as a radiation sensitizer. PATIENTS AND METHODS: Patients with metastatic RMS received 54 weeks of therapy: blocks of therapy with vincristine/irinotecan (weeks 1 to 6, 20 to 25, and 47 to 52), interval compression with vincristine/doxorubicin/cyclophosphamide alternating with etoposide/ifosfamide (weeks 7 to 19 and 26 to 34), and vincristine/dactinomycin/cyclophosphamide (weeks 38 to 46). Radiation therapy occurred at weeks 20 to 25 (primary) but was also permitted at weeks 1 to 6 (for intracranial or paraspinal extension) and weeks 47 to 52 (for extensive metastatic sites). RESULTS: One hundred nine eligible patients were enrolled, with a median follow-up of surviving patients of 3.8 years (3-year EFS for all patients, 38% [95% CI, 29% to 48%]; survival, 56% [95% CI, 46% to 66%]). Patients with one or no Oberlin risk factor (age > 10 years or < 1 year, unfavorable primary site of disease, ≥ three metastatic sites, and bone or bone marrow involvement) had a 3-year EFS of 69% (95% CI, 52% to 82%); high-risk patients with two or more risk factors had a 3-year EFS of 20% (95% CI, 11% to 30%). Toxicity was similar to that on prior RMS studies. CONCLUSION: Patients with metastatic RMS with one or no Oberlin risk factor had an improved 3-year EFS of 69% on ARST0431 compared with an historical cohort from pooled European and US studies; those with two or more risk factors have a dismal prognosis, and new approaches are needed for this very-high-risk group.
PURPOSE:Patients with metastatic rhabdomyosarcoma (RMS), except those younger than 10 years with embryonal RMS, have an estimated long-term event-free survival (EFS) of less than 20%. The main goal of this study was to improve outcome of patients with metastatic RMS by dose intensification with interval compression, use of the most active agents determined in phase II window studies, and use of irinotecan as a radiation sensitizer. PATIENTS AND METHODS: Patients with metastatic RMS received 54 weeks of therapy: blocks of therapy with vincristine/irinotecan (weeks 1 to 6, 20 to 25, and 47 to 52), interval compression with vincristine/doxorubicin/cyclophosphamide alternating with etoposide/ifosfamide (weeks 7 to 19 and 26 to 34), and vincristine/dactinomycin/cyclophosphamide (weeks 38 to 46). Radiation therapy occurred at weeks 20 to 25 (primary) but was also permitted at weeks 1 to 6 (for intracranial or paraspinal extension) and weeks 47 to 52 (for extensive metastatic sites). RESULTS: One hundred nine eligible patients were enrolled, with a median follow-up of surviving patients of 3.8 years (3-year EFS for all patients, 38% [95% CI, 29% to 48%]; survival, 56% [95% CI, 46% to 66%]). Patients with one or no Oberlin risk factor (age > 10 years or < 1 year, unfavorable primary site of disease, ≥ three metastatic sites, and bone or bone marrow involvement) had a 3-year EFS of 69% (95% CI, 52% to 82%); high-risk patients with two or more risk factors had a 3-year EFS of 20% (95% CI, 11% to 30%). Toxicity was similar to that on prior RMS studies. CONCLUSION:Patients with metastatic RMS with one or no Oberlin risk factor had an improved 3-year EFS of 69% on ARST0431 compared with an historical cohort from pooled European and US studies; those with two or more risk factors have a dismal prognosis, and new approaches are needed for this very-high-risk group.
Authors: Odile Oberlin; Annie Rey; José Sanchez de Toledo; Hélène Martelli; Meriel E M Jenney; Marcelo Scopinaro; Christophe Bergeron; Johannes H M Merks; Nathalie Bouvet; Caroline Ellershaw; Anna Kelsey; David Spooner; Michael C G Stevens Journal: J Clin Oncol Date: 2012-06-04 Impact factor: 44.544
Authors: Alberto S Pappo; Elizabeth Lyden; Phillip Breitfeld; Sarah S Donaldson; Eugene Wiener; David Parham; Kristine R Crews; Peter Houghton; William H Meyer Journal: J Clin Oncol Date: 2007-02-01 Impact factor: 44.544
Authors: Joanne J Lager; Elizabeth R Lyden; James R Anderson; Alberto S Pappo; William H Meyer; Philip P Breitfeld Journal: J Clin Oncol Date: 2006-07-20 Impact factor: 44.544
Authors: Jack F Shern; Li Chen; Juliann Chmielecki; Jun S Wei; Rajesh Patidar; Mara Rosenberg; Lauren Ambrogio; Daniel Auclair; Jianjun Wang; Young K Song; Catherine Tolman; Laura Hurd; Hongling Liao; Shile Zhang; Dominik Bogen; Andrew S Brohl; Sivasish Sindiri; Daniel Catchpoole; Thomas Badgett; Gad Getz; Jaume Mora; James R Anderson; Stephen X Skapek; Frederic G Barr; Matthew Meyerson; Douglas S Hawkins; Javed Khan Journal: Cancer Discov Date: 2014-01-23 Impact factor: 39.397
Authors: H M Maurer; E A Gehan; M Beltangady; W Crist; P S Dickman; S S Donaldson; C Fryer; D Hammond; D M Hays; J Herrmann Journal: Cancer Date: 1993-03-01 Impact factor: 6.860
Authors: Odile Oberlin; Annie Rey; Elizabeth Lyden; Gianni Bisogno; Michael C G Stevens; William H Meyer; Modesto Carli; James R Anderson Journal: J Clin Oncol Date: 2008-05-10 Impact factor: 44.544
Authors: Xiang Chen; Elizabeth Stewart; Anang A Shelat; Chunxu Qu; Armita Bahrami; Mark Hatley; Gang Wu; Cori Bradley; Justina McEvoy; Alberto Pappo; Sheri Spunt; Marcus B Valentine; Virginia Valentine; Fred Krafcik; Walter H Lang; Monika Wierdl; Lyudmila Tsurkan; Viktor Tolleman; Sara M Federico; Chris Morton; Charles Lu; Li Ding; John Easton; Michael Rusch; Panduka Nagahawatte; Jianmin Wang; Matthew Parker; Lei Wei; Erin Hedlund; David Finkelstein; Michael Edmonson; Sheila Shurtleff; Kristy Boggs; Heather Mulder; Donald Yergeau; Steve Skapek; Douglas S Hawkins; Nilsa Ramirez; Philip M Potter; John A Sandoval; Andrew M Davidoff; Elaine R Mardis; Richard K Wilson; Jinghui Zhang; James R Downing; Michael A Dyer Journal: Cancer Cell Date: 2013-12-09 Impact factor: 31.743
Authors: Sara Sannino; Christopher J Guerriero; Amit J Sabnis; Donna Beer Stolz; Callen T Wallace; Peter Wipf; Simon C Watkins; Trever G Bivona; Jeffrey L Brodsky Journal: J Cell Sci Date: 2018-09-05 Impact factor: 5.285
Authors: Monika Scheer; Tobias Dantonello; Peter Brossart; Dagmar Dilloo; Lothar Schweigerer; Simone Feuchtgruber; Monika Sparber-Sauer; Christian Vokuhl; Stefan S Bielack; Thomas Klingebiel; Ewa Koscielniak; Thekla von Kalle Journal: Pediatr Radiol Date: 2018-01-24
Authors: Kevin X Liu; Natalie B Collins; Katie A Greenzang; Elissa Furutani; Kevin Campbell; Andrew Groves; Elizabeth A Mullen; Suzanne Shusterman; Jennifer Spidle; Karen J Marcus; Brent R Weil; Christopher B Weldon; A Lindsay Frazier; Katherine A Janeway; Allison F O'Neill; Jennifer W Mack; Steven G DuBois; David S Shulman Journal: Pediatr Blood Cancer Date: 2020-07-19 Impact factor: 3.167
Authors: Abha A Gupta; Yueh-Yun Chi; James R Anderson; Elizabeth Lyden; Brenda Weigel; Carola Arndt; William H Meyer; Abby Rosenberg; Douglas S Hawkins Journal: Pediatr Blood Cancer Date: 2017-03-23 Impact factor: 3.167
Authors: Erin R Rudzinski; James R Anderson; Yueh-Yun Chi; Julie M Gastier-Foster; Caroline Astbury; Frederic G Barr; Stephen X Skapek; Douglas S Hawkins; Brenda J Weigel; Alberto Pappo; William H Meyer; Michael A Arnold; Lisa A Teot; David M Parham Journal: Pediatr Blood Cancer Date: 2017-05-18 Impact factor: 3.167
Authors: Leo Mascarenhas; Yueh-Yun Chi; Pooja Hingorani; James R Anderson; Elizabeth R Lyden; David A Rodeberg; Daniel J Indelicato; Simon C Kao; Roshni Dasgupta; Sheri L Spunt; William H Meyer; Douglas S Hawkins Journal: J Clin Oncol Date: 2019-09-12 Impact factor: 44.544
Authors: Suman Malempati; Brenda J Weigel; Yueh-Yun Chi; Jing Tian; James R Anderson; David M Parham; Lisa A Teot; David A Rodeberg; Torunn I Yock; Barry L Shulkin; Sheri L Spunt; William H Meyer; Douglas S Hawkins Journal: Cancer Date: 2018-10-23 Impact factor: 6.860
Authors: Amit J Sabnis; Christopher J Guerriero; Victor Olivas; Anin Sayana; Jonathan Shue; Jennifer Flanagan; Saurabh Asthana; Adrienne W Paton; James C Paton; Jason E Gestwicki; Peter Walter; Jonathan S Weissman; Peter Wipf; Jeffrey L Brodsky; Trever G Bivona Journal: Proc Natl Acad Sci U S A Date: 2016-07-22 Impact factor: 11.205